Latest Regulatory Challenges News

Regis Resources has reported a robust December quarter marked by record cash generation and an extended mine life at Duketon North, underpinned by disciplined costs and promising exploration results.

Australian Dairy Nutritionals reported a 152% surge in nutritional powder sales despite regulatory hurdles in Vietnam, while expanding its Future brand footprint across China.

Nyrada has secured ethics approval to begin a pivotal Phase IIa trial of its drug Xolatryp, targeting heart attack damage. Patient dosing is set to start in March 2026 across multiple Australian hospitals.

Hydrix Limited’s subsidiary has landed a significant A$2.5 million contract to develop SynCardia’s next-generation fully implantable Total Artificial Heart, marking a major step in advanced cardiovascular technology.

EQ Resources has reported a significant 33% increase in tungsten production for the December quarter, coinciding with record-breaking tungsten prices that continue to climb into 2026.

Bendigo and Adelaide Bank has been hit with a $50 million operational risk capital charge by APRA, while AUSTRAC launches an enforcement investigation into serious AML/CTF breaches. The bank commits to intensifying risk management efforts amid regulatory scrutiny.

Central Petroleum has signed a binding Letter of Intent with Northern Territory's Power and Water Corporation to fast-track drilling of four wells and establish long-term gas supply agreements through 2034.

Kingsland Minerals has initiated a Pre-feasibility Study for its Leliyn Graphite Project, partnering with Quinbrook to test graphite concentrate for battery anode applications. This marks a significant step toward developing a world-scale graphite operation in the Northern Territory.

DigiCo Infrastructure REIT appoints Michael Juniper as CEO, signaling a strategic push into advanced data centre development amid rising cloud and AI demand. Chris Maher shifts focus to government relations, underscoring regulatory challenges ahead.

SDI Limited reported a steady FY2025 with a slight profit increase, driven by growth in aesthetic and whitening products and the launch of its new amalgam replacement, Stela. The company also announced plans for a new factory to boost production capacity.

Reef Casino Trust has lodged a supplementary statement revealing delays in regulatory approvals that are likely to extend the takeover bid timeline by Iris Cairns Property. The board maintains its recommendation to accept the offer despite the uncertainty.

A former director of Emu NL has lodged a formal application with the Takeovers Panel, contesting the legitimacy of a recent $1.4 million institutional placement and alleging undisclosed attempts to influence board control.